FUROSCIX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FUROSCIX (FUROSCIX).
Furosemide inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing sodium and chloride reabsorption, leading to increased diuresis.
| Metabolism | Furosemide is primarily metabolized by glucuronidation via UGT1A1, UGT1A9, and UGT2B7; to a lesser extent by cytochrome P450 enzymes. |
| Excretion | Renal (60-80% unchanged; glucuronide metabolites account for 10-20%); biliary/fecal (<10%) |
| Half-life | Terminal half-life 1.5-2 hours in healthy; prolonged to 4-8 hours in renal impairment (CrCl <30 mL/min) and 9-19 hours in anuria |
| Protein binding | 91-99%, primarily to albumin |
| Volume of Distribution | 0.1-0.2 L/kg; higher in neonates (0.2-0.4 L/kg); restricted to extracellular fluid in adults |
| Bioavailability | Subcutaneous: 99% compared to IV; oral: 60-70% (variable due to first-pass metabolism) |
| Onset of Action | Subcutaneous: 15-30 minutes; intravenous: 5 minutes; oral: 30-60 minutes |
| Duration of Action | Subcutaneous: 2-4 hours; intravenous: 2-3 hours; oral: 4-6 hours (subcutaneous preferred for heart failure due to slower absorption and sustained effect) |
80 mg subcutaneously once daily via prefilled syringe. Maximum 80 mg/day. Administer as an adjunct to oral diuretic therapy.
| Dosage form | SOLUTION |
| Renal impairment | eGFR 15-29 mL/min/1.73m2: 40 mg subcutaneously once daily. eGFR <15 mL/min: not recommended. eGFR ≥30: no adjustment needed. |
| Liver impairment | Child-Pugh A or B: no adjustment. Child-Pugh C: use with caution; reduce dose to 40 mg subcutaneously once daily. No specific pharmacokinetic data in severe impairment. |
| Pediatric use | Safety and efficacy not established in pediatric patients (<18 years). No approved dosing available. |
| Geriatric use | Start at 40 mg subcutaneously once daily. Monitor renal function and electrolyte levels closely. Consider lower doses due to age-related decreased renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FUROSCIX (FUROSCIX).
| Breastfeeding | Furosemide is excreted into human breast milk in low amounts (M/P ratio approximately 0.2-0.5). Peak milk concentration ~0.4-0.6 µg/mL after 40 mg oral dose. Limited data suggest no adverse effects in breastfed infants. Use with caution, especially in neonates due to risk of diuresis and electrolyte imbalance. |
| Teratogenic Risk | Furosemide crosses the placenta. First trimester: Limited human data, animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Use may cause maternal hypovolemia, reduced placental perfusion, and fetal oligohydramnios; avoid if possible. Not associated with major congenital malformations. |
■ FDA Black Box Warning
Furosemide can cause profound diuresis with water and electrolyte depletion, leading to serious adverse events such as circulatory collapse and thromboembolic complications. Careful medical supervision is required.
| Serious Effects |
["Anuria","Severe hypokalemia","Severe hyponatremia","Hypersensitivity to furosemide or sulfonamides","Hepatic coma or pre-coma"]
| Precautions | ["Monitor for electrolyte disturbances (e.g., hypokalemia, hyponatremia, hypomagnesemia, hypocalcemia)","May cause ototoxicity, especially with rapid injection or high doses","Risk of renal impairment; monitor renal function","Can exacerbate systemic lupus erythematosus","Avoid in patients with known sulfonamide allergy"] |
Loading safety data…
| Fetal Monitoring | Maternal: Monitor blood pressure, serum electrolytes (sodium, potassium, chloride, bicarbonate), renal function, and fluid balance. Fetal/neonatal: Assess fetal growth and amniotic fluid volume via ultrasound; monitor newborn for electrolyte disturbances and dehydration, especially if maternal use close to delivery. |
| Fertility Effects | No established effect on fertility in humans. In animal studies, no impairment of fertility observed at clinically relevant doses. |